Companies - Kiadis Pharma

Price

 
Price
€ 8,40
Change
€ -0,28
Change %
-3,23%
Open
€ 8,68
High
€ 8,68
Low
€ 8,30
Volume
156.722

Profile

 
Profile
Kiadis Pharma is a pharmaceutical company in the clinical development stage focused on research, development and future commercialization of cellular immunotherapy products for the treatment of blood cancers and inherited blood diseases.
Industry
Biotechnology
Description
Companies in the biotechnology industry are performing research and development activities for the purpose of discovering new drugs and diagnostics. The turnover of these companies comes from sales of these products or the sale of licenses of drugs and diagnostic to other companies.

Key figures (2017)

 
The ratios below are calculated using the last known share price and the last known company financials.

Ratios per share

Price to Earnings
-8,523
Price to Earnings (3 years)
-9,023
Price to Earnings (5 years)
-11,528
Price to earnings growth
-
Price/cashflow
-8,614
Price/net cashflow
9,455
Price/book value
-
Price to sales
-

Ratios for dividend

Dividend yield
-
Pay out
-

Valuation ratios

Market value/PE
-
Market value/turnover
-
Enterprise value/turnover
-

Return ratios

Return on private equity
-
Return on total equity
-38,13%
Profit margin
-

Risk ratios

Solvability
-
Solvability
-
Current ratio
5,966
Debt to Equity
-

Value invest ratios

Grahams Number
-
Grahams Value
-
Grahams Product
-
Grahams Product (3 years)
-

2017

 

Profit and loss

Net profit (x 1 mln)
€ -17,04
Turnover (x 1 mln)
-
Cashflow(x 1 mln)
€ -16,86
Net cashflow(x 1 mln)
€ 15,36

Balance

Private equity (x 1 mln)
-
Foreign equity (x 1 mln)
-
Current assets (x 1 mln)
€ 31,26
Current liabilities (x 1 mln)
€ 5,24
Working capital (x 1 mln)
€ 26,02
Balance total (x 1 mln)
€ 44,69

Share

Outstanding shares (x 1 mln)
17,290
Price year-end
€ 7,92
Dividend per share
-
Earnings per share
€ -0,99
Cashflow per share
€ -0,98
Net cashflow per share
€ 0,89
Book value per share
-
Stockmarket value (x 1 mln)
€ 136,95

History

 
Year
2017
2016
2015
2014
2013
Net profit (x 1 mln)
€ -17,04
€ -14,79
€ -16,46
€ -7,81
€ -6,89
Turnover (x 1 mln)
-
-
-
-
-
Price year-end
€ 7,92
€ 8,45
€ 12,26
-
-
Year high
€ 12,40
€ 12,50
€ 12,85
-
-
Year low
€ 5,11
€ 6,93
€ 10,55
-
-
Outstanding shares (x 1 mln)
17,290
13,755
12,057
10,471
10,896
Price to Earnings
-8,037
-7,861
-8,977
-
-
Earnings per share
€ -0,99
€ -1,08
€ -1,37
€ -0,75
€ -0,63
Dividends
-
-
-
-
-
Dividend yield
-
-
-
-
-
Pay out
-
-
-
-
-
Private equity (x 1 mln)
-
€ 9,44
€ 25,65
€ 2,67
€ 5,36
PE per share
-
€ 0,69
€ 2,13
€ 0,25
€ 0,49
Balance total (x 1 mln)
€ 44,69
€ 29,22
€ 42,28
€ 20,21
€ 20,19
Stockmarket value (x 1 mln)
€ 136,95
€ 116,27
€ 147,76
-
-

Company analysis

 

Analysis of profit indicators

Average profit per share (5 years)
€ -1,10
Standard deviation average profit
€ 0,35 (-31,57%)
Average annual growth rate
-10,51%
Compound annual growth percentage
-11,46%
© 2009 Skuzet. All Rights Reserved.